Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During his career he achieved together with its different teams to bring four drug candidates from research to the clinics (up to phase IIb). Overall, he has raised as of now a total of more than €160 million from VCs and strategic partners in Europe, USA, Japan and Korea and have had numerous successes in the sale and initial public offering of biotechnology companies. He is President and CEO of the biotechnology company PDC-Line Pharma and board member of Cell Matters. He was also a Board Member of the French biotechnology company Vivalis/Valneva and the Belgian company Bioxodes, the Health Cluster of Wallonia BIOWIN and the industrial association European Biotechnology Entreprises (EBE). Eric have been as well co-Inventor of the first worldwide GMP approved mobile manufacturing unit for cell therapy (WO 2014049151 A). He worked for 12 years as a Principal in the Healthcare and Life Sciences Practice of Arthur D. Little where he led work in the areas of strategy, M&A and technology & innovation management. He is co-founder of 4 biotechnology companies called Myosix, Murigenetics, Digital-Orthopaedics and HairClone. -Myosix is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been bought by Genzyme mid-2002. -Murigenetics is a Biotechnology company developing therapies for genetic disorders. -Digital Orthopaedics is a Digital Health company providing access to a comprehensive Clinical Decision Support System for musculoskeletal pathologies. -HairClone is a Biotechnology company developing cell-based hair treatments and Follicle Banking Service. Eric worked for IsoHealthcare Group (eventually acquired by the Monitor Group) as a Senior Consultant where I focused on leading healthcare and life sciences issues. He also worked as a strategic marketing Manager for the “Centre Européen de Bioprospective” and as project leader in the corporate R&D centre of Zeneca in UK. Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.